References

tumors

Malignant tumours

2224-50572587-6813

Rosoncoweb

10.18027/2224-5057-2013-1-35-40

tumors-20

Research Article

ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ

ORIGINAL REPORTS

РАННИЙ РАК МОЛОЧНОЙ ЖЕЛЕЗЫ. РАЗЛИЧНЫЕ АСПЕКТЫ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ. НОВЫЕ ПОДХОДЫ К НЕОАДЪЮВАНТНОЙ ТЕРАПИИ РАННЕГО HER2 ПОЗИТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

Early breast cancer. Different aspects of combined treatment. New approaches in neoadjuvant treatment of early HER2-positive breast cancer.

Сакаева

Д. Д.

Sakaeva

V. V.

d_sakaeva@mail.ru

ГБУЗ Республиканский клинический онкологический диспансер МЗ РБRussian Federation

2013

20052015

013540

2015

Сакаева Д.Д.

Sakaeva V.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.malignanttumors.org/jour/article/view/20

Опыт применения препаратов, блокирующих HER2-рецепторы, в клинической практике насчитывает около 15 лет. За это время произошла серьезная эволюция наших представлений о месте и показаниях к назначению этих препаратов при HER2-позитивном раке молочной железы. Доказано, что неоадъювантная таргетная терапия раннего HER2-позитивного рака молочной железы уменьшает риск рецидивирования и метастазирования. Тем не менее, блокирование HER2-рецепторов при раннем раке молочной железы оставляет множество открытых вопросов. Применение таргетных препаратов в неоадъювантном режиме является перспективным и требует продолжения исследований.

Experience of using of HER2-antagonists in clinical practice has approximately 15 years. During this time there was a serious evolution of our understanding of the place and indications for these drugs in HER2-positive breast cancer. It was proved that neoadjuvant targeted therapy of early HER2-positive breast cancer reduces the risk of recurrence and metastasis. However, in the issue on blocking of HER2-receptors in early breast cancer many questions are still remained. The use of targeted drugs in the neoadjuvant treatment is promising and requires further research.

HER2-позитивный рак молочной железынеоадъювантная терапия

HER2-positive breast cancerneoadjuvant treatment

References1

Bear H. D. Indications for neoadjuvant chemotherapy for breast cancer. Semin. Oncol. — 1998; 25: 3.

Hortobagyi G. N., Blumenschein G. R., Spanos W. et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer. — 1983; 51: 763.

Hortobagyi G. N., Ames F. C., Buzdar A. U. et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. — 1988; 62: 2507.

Hortobagyi G. N. Comprehensive management of locally advanced breast cancer.Cancer. — 1990; 66: 1387.

Fisher B., Bryant J., Wolmark N. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. — 1998; 16: 2672.

Wolmark N., Wang J., Mamounas E. et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. — 2001; 30: 96-102.

Bear H. D., Anderson S., Brown A. et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. — 2003; 21: 4165-4174.

Van der Hage J. A., van de Velde C. J. H, Julien J-P et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. — 2001; 19:4224-4237.

Mieog S., van der Hage J., van de Velde C. J. H. Preoperative Chemotherapy for Women with Operable Breast Cancer (Review) 1. John Wiley & Sons, Ltd. January 24 [epub ahead of print],

DOI: 10.1002 / 14651858. CD005002.

Kuerer H. M., Newman L. A., Smith T. M. et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. — 1999;17: 460-469.

Guarneri V., Broglio K., Kau S-W et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. — 2006; 24: 1037-1044.

von Minckwitz G., Kaufmann M., K mmel S. et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline- taxane + / – trastuzumab containing chemotherapy. Cancer Res. — 2009; 69 (suppl.): 79.

Ring A. E., Smith I. E., Ashley S. et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. — 2004; 91: 2012-2017.

Colleoni M. Preoperative systemic treatment: Prediction of responsiveness. Breast 2003; 12 (suppl 1, abstr S35): S13.

Esserman L. J., Perou C., Cheang M. et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007 / 150012, ACRIN 6657). ASCO Meeting Abstracts, 2009 (LBA515).

Slamon D. J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. — 2001; 344: 783.

Pritchard K. I., Messersmith H., Elavathil L. et al. HER2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. — 2008; 26: 736-744.

Di Leo A., Desmedt C., Bartlett J. M. S. et al. HER2 and TOP2A as predictive markers for anthracycline containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. — 2011;12: 1134-1142.

Hayes D. F., Thor A. D., Dressler L. G. HER2 and response to paclitaxel in node- positive breast cancer. N Engl J Med. — 2007; 357: 1496-1506.

Kaufmann M., von Minckwitz G., Bear H. D. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. — 2007; 18:1927-1934.

Buzdar A. U., Ibrahim N. K., Francis D. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermalgrowth factor receptor 2-positive operable breast cancer. J Clin Oncol. — 2005; 23:3676-3685.

Buzdar A. U., Valero V., Ibrahim N. K. et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor-2 positive operable breast cancer: an update

of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. — 2007;13: 228-233.

Gianni L., Eiermann W., Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. — 2010; 375: 377-384.

Untch M., Rezai M., Loibl S. et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. — 2010;

: 2024-2031.

von Minckwitz G., Rezai M., Loibl S. et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncolм 2010; 28:2015-2023.

Семенова А. И. Основные принципы системной терапии позитивного рака молочной железы. Практическая онкология. – Т.11. – № 4. – 2010. – с. 239-246.

Jobnston S., Trudeau M., Kaufman B. еt al Phase II study of predictive biomarker profails for response targeting human epidermal growth factor receptor 2 (HER2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. — 2008; 26: 1066-1072.

Baselga J., Bradbury I., Eidtmann H. et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. — 2012; 379: 633-640.

Untch M., Loibl S., Bischoff J. et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG44): a randomised phase 3 trial. Lancet Oncol. — 2012; 13: 135-144.

Guarneri V., Frassoldati A., Bottini A. et al. Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. — 2012; 30: 1989-1995.

Gianni L., Pienkowski T., Im Y-H et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere’). Cancer Res. — 2010; 70 (24 Suppl.): Abstr S3–2.

Baselga J., Cort s J., Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. — 2012; 366: 2.

Blackwell K. L., Burstein H. J., Storniolo A. M. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. — 2010; 28:

Sousa B., Cardoso F. Neoadjuvant treatment for HER2-positiv and tripl-negativ breast cancer. Ann Oncol. — 2012; 23: 237-242.

The authors declare that there are no conflicts of interest present.